Christopher Richard Anzalone Sells 12,563 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) CEO Christopher Richard Anzalone sold 12,563 shares of the company's stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $19.59, for a total value of $246,109.17. Following the transaction, the chief executive officer now directly owns 3,775,772 shares in the company, valued at $73,967,373.48. This trade represents a 0.33 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Christopher Richard Anzalone also recently made the following trade(s):

• On Wednesday, December 18th, Christopher Richard Anzalone sold 26,712 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $21.24, for a total transaction of $567,362.88.

Arrowhead Pharmaceuticals Stock Up 1.5 %

ARWR traded up $0.30 during trading on Monday, reaching $19.75. The company had a trading volume of 1,399,220 shares, compared to its average volume of 1,284,027. The company has a market cap of $2.46 billion, a P/E ratio of -3.93 and a beta of 0.91. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $17.05 and a 12 month high of $39.83. The company has a debt-to-equity ratio of 2.06, a current ratio of 6.74 and a quick ratio of 6.74. The business's fifty day moving average price is $21.26 and its 200 day moving average price is $22.99.

Analyst Ratings Changes

A number of analysts have commented on ARWR shares. HC Wainwright reaffirmed a "buy" rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a report on Friday. Citigroup decreased their price objective on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a "neutral" rating for the company in a research note on Wednesday, November 27th. Sanford C. Bernstein dropped their price objective on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a "market perform" rating for the company in a report on Friday, November 29th. Chardan Capital restated a "buy" rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Thursday, December 12th. Finally, Piper Sandler lowered their price target on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an "overweight" rating for the company in a research note on Wednesday, November 27th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, Arrowhead Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $42.70.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Avoro Capital Advisors LLC increased its holdings in Arrowhead Pharmaceuticals by 3.9% during the 2nd quarter. Avoro Capital Advisors LLC now owns 8,888,888 shares of the biotechnology company's stock worth $231,022,000 after purchasing an additional 333,333 shares in the last quarter. State Street Corp grew its holdings in shares of Arrowhead Pharmaceuticals by 8.8% during the third quarter. State Street Corp now owns 6,354,331 shares of the biotechnology company's stock worth $123,083,000 after buying an additional 516,569 shares in the last quarter. Geode Capital Management LLC raised its position in Arrowhead Pharmaceuticals by 0.9% in the 3rd quarter. Geode Capital Management LLC now owns 2,964,119 shares of the biotechnology company's stock valued at $57,426,000 after buying an additional 26,171 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Arrowhead Pharmaceuticals by 2.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,085,069 shares of the biotechnology company's stock worth $28,201,000 after acquiring an additional 30,086 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in Arrowhead Pharmaceuticals by 1.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,006,935 shares of the biotechnology company's stock worth $19,504,000 after acquiring an additional 12,574 shares during the last quarter. 62.61% of the stock is owned by institutional investors.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.